OakChart

Oragenics Inc

OGENHealthcare·Biotechnology·USA·Nano·AMEX·Nov 13 • 7:02 AM ET

0.21-0.14 (-40.00%)
2026-11-13 13:02 CET
Market cap
-
Revenue, TTM
0.00 USD m
Net income, TTM
-10.08 USD m
Free cash flow, TTM
-10.21 USD m
EPS diluted, TTM
-3.58
Price / earnings
-
Compare

Price

OGEN against its 20, 50 and 200-day averages
Terms2050200
Patternshover a marker to name it
RS 0Sales 0.00Price0.000.200.400.600.801.0015.9M31.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26OGENclose 0.2120-day 0.3750-day 0.44200-day 0.580.21

82.8% under the 52-week high of 1.22 on 13 Nov 2025. 52-week low 0.19 on 13 Nov 2026. Last 15 sessions, 119.4% high to low

Volume 70.40× normal · the line is the 50-bar volume average

Setup. RS line 0
CANSLIM 2 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50% — not on the tape: EPS Growth This Year: High (>25%)
VCP 2 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Relative Volume: Under 1
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 1 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 1 of 4 — fails: 52-Week High/Low: New High; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 1 of 4 — fails: Return on Equity: Over +15% — not on the tape: EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%)
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 2 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 0 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200

Profile

OGEN
52-week range, 2% of the way up
0.191.22

Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its technology and pipeline consist of antibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Lakewood Ranch, FL.

Employees3
IPOOct 21, 2003
Beta1.27
ATR, 14d0.04
Rel volume70.40
Short float18.57%
Insider own0.17%
Inst own2.40%

Snapshot

6 groups

Valuation

Index-
Market Cap$950000.00
Enterprise Value-2.91M
Income-10.08M
Sales0.00M
Book / share0.81
Cash / share0.86
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees3
IPOOct 21, 2003

Ratios

Price / earnings-
Forward price / earnings-
Price / earnings / growth-
Price / sales-
Price / book0.26
Price / cash0.25
Price / free cash flow-
Value / cash profit-
Value / sales-
Quick Ratio3.01
Current Ratio3.01
Debt / equity0.00
Long-term debt / equity0.00
Options and shortNo / Yes

Earnings

Earnings / share-3.58
Earnings next year-
Earnings next quarter-
Earnings this year-
Earnings next year-
Earnings growth, 5 years-
Past earnings growth72.24% 64.78%
Past sales growth- -
Earnings vs last year86.26%
Sales vs last year-
Earnings vs last quarter81.61%
Sales vs last quarter-
Earnings-
Surprise- -

Ownership

Insiders own0.17%
Insider trades0.00%
Institutions own2.40%
Institution trades-2.41%
Return on assets-264.23%
Return on equity-1307.06%
Return on capital-274.70%
Gross Margin-
Operating margin-
Profit Margin-
20-day average-43.22%
50-day average-52.13%
200-day average-63.77%

Technical

Shares out4.51M
Shares floating4.50M
Short / float18.57%
Short ratio1.62
Short interest0.84M
52-week high1.22 -82.8%
52-week low0.19 +9.9%
Volatility7.57% 6.72%
Average range0.04
Strength index14.80
Market sensitivity1.27
Relative volume70.40
Avg Volume516.66K
Volume1,818,638

Performance

Perf Week-39.88%
Perf Month-51.86%
Perf Quarter-60.77%
Perf Half Y-64.33%
Perf YTD-73.20%
Perf Year-81.59%
Perf 3Y-99.81%
Perf 5Y-99.98%
Perf 10Y-100.00%
Recommendation1.00
Target Price2.00
Prev Close0.35
Price0.21
Change %-40.05%

Peers

Mkt cap
TickerCompanyMkt cap
SILOSILO Pharma Inc2.93M
JUNSJupiter Neurosciences Inc2.45M
NRSNNeuroSense Therapeutics Ltd3.36M
ALZNAlzamend Neuro Inc6.17M
VTGNVistagen Therapeutics Inc7.98M
ENVBEnveric Biosciences Inc6.80M
ANVSAnnovis Bio Inc36.16M
TNXPTonix Pharmaceuticals Holding Corp62.77M
KTTAPasithea Therapeutics Corp19.38M
QNTMQuantum BioPharma Ltd12.46M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Telling FredDirectorDec 12 '25Sale0.9421019834,538Dec 15 04:38 PM
Frederick W. TellingDirectorDec 12 '25Proposed Sale0.91210192Dec 12 06:28 PM

News

latest 14 of 200
  • Oragenics: Q3 Earnings Snapshot (Associated Press) -40.05%
  • Oragenics Receives NYSE American Approval of Compliance Plan and Extension Through February 2028 (GlobeNewswire)
  • Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum (GlobeNewswire)
  • Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update (GlobeNewswire)
  • Oragenics: Q2 Earnings Snapshot (Associated Press)
  • Oragenics Achieves Full Activation of Australian Phase IIa Trial Network - All Three Sites Now Enrolling (GlobeNewswire)
  • Sidoti Events, LLC's May Micro-Cap Virtual Conference (ACCESSWIRE)
  • Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21 (GlobeNewswire)
  • ORAGENICS PROVIDES INVESTOR UPDATE (GlobeNewswire)
  • Oragenics: Q1 Earnings Snapshot (Associated Press) -6.60%
  • Oragenics Signs Letter of Intent to License CardioDialysis Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation (GlobeNewswire)
  • Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury. (GlobeNewswire)
  • Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury (GlobeNewswire)
  • Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury (GlobeNewswire) +12.95%

Quarterly earnings

2022Q3 EPS -54.000, from -72.000 a year earlier. Sales 0.10, from 0.00 a year earlier
EPS
0.0000-1082020Q4 EPS -90.000 against -10820Q42021Q1 EPS -90.00021Q12021Q2 EPS -0.90021Q22021Q3 EPS -72.000 against -72.00021Q32021Q4 EPS -36.000 against -72.00021Q42022Q1 EPS -90.000 against -36.00022Q12022Q2 EPS -54.000 against -72.00022Q22022Q3 EPS -54.00022Q3
Sales, USD millions
0.1002020Q4 sales 0.00 against 0.0020Q42021Q1 sales 0.0021Q12021Q2 sales 0.0021Q22021Q3 sales 0.00 against 0.0021Q32021Q4 sales 0.10 against 0.0021Q42022Q1 sales 0.00 against 0.0022Q12022Q2 sales 0.00 against 0.0022Q22022Q3 sales 0.1022Q3

The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.

PeriodReportedEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mSurpriseYear-ago quarterAnalystsNext session
2022Q3ended 2022-09-302022-11-14 08:30-54.000--59.6700.10-EPS - · sales -vs 2021Q3, year-ago quarter · EPS -25.0% · sales --Open -2.99% vs SPY -0.46%. Close +4.48% vs SPY -0.85%
2022Q2ended 2022-06-302022-08-09 16:30-54.000-72.000-62.3700.000.00EPS -25.0% · sales -vs 2021Q2, year-ago quarter · EPS +5900.0% · sales -1Open +0.18% vs SPY +1.81%. Close -1.11% vs SPY +2.10%
2022Q1ended 2022-03-312022-05-13 08:30-90.000-36.000-70.9920.000.00EPS +150.0% · sales -vs 2021Q1, year-ago quarter · EPS 0.0% · sales -1Open +0.67% vs SPY +1.11%. Close +12.84% vs SPY +2.39%
2021Q4ended 2021-12-312022-03-24 16:30-36.000-72.000-35.4600.100.00EPS -50.0% · sales -vs 2020Q4, year-ago quarter · EPS -60.0% · sales -1Open -5.00% vs SPY +0.15%. Close -10.46% vs SPY +0.49%
2021Q3ended 2021-09-302021-11-07-72.000-72.000-67.8780.000.00EPS 0.0% · sales -vs 2020Q3, year-ago quarter · EPS -50.0% · sales -1Open +0.55% vs SPY +0.60%. Close -0.31% vs SPY +0.43%
2021Q2ended 2021-06-302021-08-16 08:30-0.900--59.2740.00-EPS - · sales -vs 2020Q2, year-ago quarter · EPS -99.8% · sales -1Open +2.08% vs SPY -0.31%. Close -7.20% vs SPY +0.24%
2021Q1ended 2021-03-312021-05-03-90.000--91.2420.00-EPS - · sales -vs 2020Q1, year-ago quarter · EPS -54.5% · sales --Open +1.94% vs SPY +0.51%. Close -9.00% vs SPY +0.22%
2020Q4ended 2020-12-312021-03-01 08:30-90.000-108-89.4960.000.00EPS -16.7% · sales -vs 2019Q4, year-ago quarter · EPS -37.5% · sales --Open +2.94% vs SPY +1.38%. Close 0.00% vs SPY +2.42%
2020Q3ended 2020-09-302020-11-10 08:30-144-126-135.650.000.00EPS +14.3% · sales -vs 2019Q3, year-ago quarter · EPS 0.0% · sales --Open +0.53% vs SPY -0.30%. Close -4.17% vs SPY -0.15%
2020Q2ended 2020-06-302020-08-14 08:30-432-162-425.230.000.00EPS +166.7% · sales -vs 2019Q2, year-ago quarter · EPS +140.0% · sales --Open -1.02% vs SPY -0.12%. Close -7.37% vs SPY +0.00%
2020Q1ended 2020-03-312020-05-15 08:30-198-144-202.450.000.00EPS +37.5% · sales -vs 2019Q1, year-ago quarter · EPS 0.0% · sales -3 EPS · 1 salesOpen -1.75% vs SPY -0.91%. Close -3.07% vs SPY +0.46%
2019Q4ended 2019-12-312020-03-04 08:30-144-174.01-140.380.000.00EPS -17.2% · sales -vs 2018Q4, year-ago quarter · EPS -11.1% · sales -3 EPS · 2 salesOpen -0.10% vs SPY +1.96%. Close +4.23% vs SPY +4.20%
2019Q3ended 2019-09-302019-11-14 08:30-144-162-149.720.000.00EPS -11.1% · sales -vs 2018Q3, year-ago quarter · EPS +1271.4% · sales -3 EPS · 2 sales-
2019Q2ended 2019-06-302019-08-14 08:30-180-120.01-187.60.000.00EPS +50.0% · sales -vs 2018Q2, year-ago quarter · EPS +1478.9% · sales -2 EPS · 1 sales-
2019Q1ended 2019-03-312019-05-13 08:30-198-156.01-195.930.000.00EPS +26.9% · sales -vs 2018Q1, year-ago quarter · EPS +1471.4% · sales ---
2018Q4ended 2018-12-312019-03-29 08:30-162-180-168.520.000.00EPS -10.0% · sales -vs 2017Q4, year-ago quarter · EPS +1700.0% · sales ---

Annual earnings

2024FY EPS -22.800. Sales 0.00
EPS
0.0000-3,4202016FY EPS -3,42020162017FY EPS -2,46620172018FY EPS -1,566 against -1,47620182019FY EPS -68420192020FY EPS -846 against -82820202021FY EPS -25220212022FY EPS -288 against -28820222024FY EPS -22.8002024
Sales, USD millions
1.0302013FY sales 1.0320132014FY sales 0.9420142018FY sales 0.00 against 0.0020182019FY sales 0.0020192020FY sales 0.00 against 0.0020202021FY sales 0.1020212022FY sales 0.10 against 0.1020222024FY sales 0.002024

Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.

earnings feed, not the snapshot. Not the statement ratio.

PeriodEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mP/E, earnings feed
2029FYestimate-0.290--45.000.72
2028FYestimate--0.390--2.25-
2027FYestimate--0.420----
2026FYestimate--0.690----
2025FYestimate--0.760-4.563-0.00-
2024FY-22.800--0.8700.00--
2022FY-288-288-213.350.100.10-
2021FY-252--250.450.10--
2020FY-846-828-841.570.000.00-
2019FY-684--662.630.00--
2018FY-1,566-1,476-1,5640.000.00-
2017FY-2,466--2,460---
2016FY-3,420--3,417---
2014FY-2,880--2,8800.94--
2013FY-10,080--10,0801.03--
2012FY-13,320-7,200-13,3201.331.40-

Quarterly results

2026Q2 revenue 0.00, from 0.00 a year earlier. 2023Q3 operating margin -20,900%
Revenue, USD millions
0.890-0.892024Q3 revenue 0.0024Q32024Q4 revenue 0.0024Q42025Q1 revenue 0.0025Q12025Q2 revenue 0.0025Q22025Q3 revenue 0.0025Q32025Q4 revenue 0.0025Q42026Q1 revenue 0.0026Q12026Q2 revenue 0.0026Q2

From the quarterly statement. Not an estimate.

Estimate revisions

Latest snapshot of each period and type. 2025FY E -0.76 per share.
PeriodTypeScaleDateMeanvs prior date
2025FYEper share2025-10-28-0.760.0%
2025FYSper share2025-10-280.00-

Estimate history

Annual
Metric201720182019202020212022202320242025TTMMRQ
EPS per share-2459.7-1563.534-662.634-841.572-250.452-213.354-275.447-47.877-4.563-3.5828-
Sales USD millions0000000000-
Shares million shares000000004-5
Quarterly
MetricQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
EPS per share-15.269-11.318-7.993-3.651-3.105-1.965-0.535-0.512-0.571
Sales USD millions000000000
Shares million shares000114445

Income statement, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/2018
Total Revenue0.000.000.000.000.00-100.0%0.090.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.00-100.0%0.03-25.0%0.040.0%0.04-20.0%0.05-16.7%0.06+100.0%0.03
Gross Profit0.000.000.00-0.03-0.04-180.0%0.05-0.05-0.06-0.03
Selling, General and Administrative Excl. Other10.479.36-11.4%10.56-0.8%10.64-26.6%14.50-8.3%15.82-40.5%26.59+68.2%15.81+58.7%9.96
Research and Development3.422.39-41.8%4.11-20.8%5.19-48.3%10.03-4.8%10.54-52.2%22.06+82.0%12.12+103.0%5.97
Other Operating Expense0.000.000.000.00-100.0%0.010.000.000.000.00
Operating Income-10.47-9.36-10.56-10.67-14.55-15.77-26.64-15.88-10.00
Interest Expense0.020.79+2533.3%0.030.0%0.03+50.0%0.020.0%0.02+100.0%0.010.0%0.010.0%0.01
Unusual Expense0.000.000.00-100.0%10.270.000.00-0.13-0.00
Net Income Before Taxes-10.29-9.98-10.57-20.66-14.29-15.71-26.43-15.57-9.91
Income Taxes-0.21-0.140.000.000.000.000.000.000.00
Consolidated Net Income-10.08-9.84-10.57-20.66-14.29-15.71-26.43-15.57-9.91
Net Income From Continuing Operations-10.08-9.84-10.57-20.66-14.29-15.71-26.43-15.57-9.91
Net Income-10.08-9.84-10.57-20.66-14.29-15.71-26.43-15.57-11.33
EPS (Recurring) per share-2.28-4.56-47.88-179.55-213.35-250.45-844.53-662.63-1,563.54
EPS (Basic, Before Extraordinaries) per share-3.58-4.56-47.88-275.45-213.35-250.45-841.57-662.63-1,563.53
EPS (Diluted) per share-3.58-4.56-47.88-275.45-213.35-250.45-841.57-662.63-1,563.53
EBITDA-10.47-9.36-10.56-10.64-14.51-15.73-26.59-15.82-9.97
Non-Operating Income (Expense)0.200.17+750.0%0.02-93.8%0.32+14.3%0.28+250.0%0.08-11.1%0.09-71.9%0.32+255.6%0.09
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.450.44-15.4%0.52-49.0%1.02+37.8%0.74-56.2%1.69+13.4%1.49+170.9%0.55-45.0%1.00
Price To Sales Ratio ratio-----578.96---
Gross Margin %-----52.59---
Operating Margin %------18,131.88---
Net Margin %------18,062.03---
Shares Outstanding million shares4.514.27+916.7%0.42+320.0%0.10+42.9%0.07+16.7%0.06+20.0%0.05+66.7%0.03+50.0%0.02
Market Capitalization1.581.58-65.9%4.64-67.9%14.46+17.3%12.33-76.2%51.91+26.0%41.20+70.8%24.12-4.6%25.28

Income statement, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/20242024Q39/30/2024
Total Revenue0.000.000.000.000.000.000.000.00-100.0%
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other2.59+51.5%2.26+11.3%2.50-25.6%3.12+27.9%1.71-26.0%2.03-17.5%3.36+33.3%2.44+16.2%
Research and Development1.18+162.2%0.65+91.2%0.67-59.9%0.93+5.7%0.45-50.5%0.34-48.5%1.67+116.9%0.88+15.8%
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.59-2.26-2.50-3.12-1.71-2.03-3.36-2.44
Interest Expense0.00-100.0%0.00-100.0%0.010.0%0.010.0%0.570.20+1900.0%0.010.0%0.010.0%
Unusual Expense0.000.000.000.000.000.000.00-100.0%0.00
Net Income Before Taxes-2.58-2.22-2.42-3.07-2.27-2.22-3.35-2.46
Income Taxes-0.05-0.02-0.140.000.000.000.000.00
Consolidated Net Income-2.53-2.20-2.29-3.07-2.27-2.22-3.35-2.46
Net Income From Continuing Operations-2.53-2.20-2.29-3.07-2.27-2.22-3.35-2.46
Net Income-2.53-2.20-2.29-3.07-2.27-2.22-3.35-2.46
EPS (Recurring) per share-0.57-0.51-0.54-1.96-3.10-3.65-7.99-11.32
EPS (Basic, Before Extraordinaries) per share-0.57-0.51-0.54-1.96-3.10-3.65-7.99-11.32
EPS (Diluted) per share-0.57-0.51-0.54-1.96-3.10-3.65-7.99-11.32
EBITDA-2.59-2.26-2.50-3.12-1.71-2.03-3.36-2.44
Non-Operating Income (Expense)0.02+100.0%0.04+300.0%0.08+300.0%0.060.010.01-50.0%0.02-66.7%-0.02-120.0%
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.010.0%0.020.0%0.41+583.3%0.01-97.0%0.01-83.3%0.02-71.4%0.06-87.2%0.33-17.5%
Shares Outstanding million shares4.51+450.0%4.38+508.3%4.27+916.7%4.13+1232.3%0.82+331.6%0.72+380.0%0.42+320.0%0.31+244.4%
Market Capitalization1.58-42.1%2.43-46.1%3.26-29.7%5.41+51.1%2.73-41.4%4.51+1.6%4.64-67.9%3.58-40.4%

Balance sheet, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/20182017FY12/31/2017
Cash & Short Term Investments8.40+876.7%0.86-75.3%3.48-69.6%11.43-58.1%27.27+54.6%17.64-3.4%18.27-9.6%20.21+227.6%6.17
Short Term Receivables0.050.000.000.00-100.0%0.010.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.61+163.9%0.61+60.5%0.38-86.7%2.86+565.1%0.43+26.5%0.34-40.4%0.57-66.9%1.72+67.0%1.03
Total Current Assets10.07+585.0%1.47-62.0%3.87-72.9%14.29-48.4%27.71+54.1%17.98-4.6%18.84-14.1%21.93+205.0%7.19
Net Property, Plant & Equipment0.000.00-100.0%0.01-97.9%0.47-9.6%0.52-25.7%0.70-23.1%0.91+658.3%0.12+500.0%0.02
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable--------0.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets0.000.00-100.0%1.090.000.000.000.000.000.00
Total Assets10.07+585.0%1.47-70.4%4.97-66.3%14.76-47.7%28.23+51.1%18.68-5.4%19.75-10.4%22.05+205.8%7.21
Short Term Debt Incl. Current Port. of LT Debt0.23-30.3%0.33+3.1%0.32-31.9%0.47-6.0%0.50+22.0%0.41+32.3%0.31+158.3%0.12+50.0%0.08
Accounts Payable1.56+36.8%1.14-8.1%1.24+396.0%0.25-70.6%0.85+157.6%0.33-72.7%1.21+45.8%0.83+33.9%0.62
Other Current Liabilities0.00-100.0%0.21-8.7%0.23-73.9%0.88+877.8%0.09-85.2%0.61+84.8%0.33+57.1%0.21+5.0%0.20
Total Current Liabilities1.79+6.5%1.68-6.7%1.80+12.5%1.60+10.3%1.45+8.2%1.34-27.6%1.85+58.1%1.17+30.0%0.90
Long Term Debt0.000.000.00-100.0%0.15-50.0%0.30-38.8%0.49-26.9%0.670.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities1.79+6.5%1.68-6.7%1.80+2.9%1.75+0.6%1.74-5.4%1.84-27.0%2.52+115.4%1.17+30.0%0.90
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.00-100.0%1.590.0%1.59-40.2%2.66-62.9%7.17+10.1%6.51+6.7%6.10-3.3%6.31
Common Equity8.28-0.21-113.3%1.58-86.2%11.42-52.1%23.83+146.4%9.67-9.8%10.72-27.5%14.78+147700.0%0.01
Total Shareholders Equity8.28-0.21-106.6%3.17-75.6%13.01-50.9%26.49+57.3%16.84-2.3%17.23-17.5%20.88+230.4%6.32
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity8.28-0.21-106.6%3.17-75.6%13.01-50.9%26.49+57.3%16.84-2.3%17.23-17.5%20.88+230.4%6.32
Total Liabilities & Stockholders Equity10.07+585.0%1.47-70.4%4.97-66.3%14.76-47.7%28.23+51.1%18.68-5.4%19.75-10.4%22.05+205.8%7.21
Book Value Per Share per share1.94-0.51-103.3%15.34-90.9%169.17-54.1%368.51+94.3%189.67-54.7%418.28-53.7%903.99+36797.6%2.45
Tangible Book Value Per Share per share1.94-0.51-103.3%15.34-90.9%169.17-54.1%368.51+94.3%189.67-54.7%418.28-53.7%903.99+36797.6%2.45
Full-Time Employees people30.0%3-40.0%5-16.7%6+20.0%5-28.6%70.0%7+16.7%60.0%6
Price to Book Ratio ratio0.43-21.912.950.902.184.262.251.71-49.78
Return on Assets %-170.58-328.26-209.44-66.47-66.98-137.54-74.47-67.76-116.52
Return on Equity %-243.94-714.95-255.36-72.35-72.52-155.13-81.68-72.90-144.57
Return on Invested Capital %-118.85--651.98-108.56-58.66-152.44-86.95-47.48-106.57
Quick Ratio ratio5.640.872.158.9519.1713.4010.1818.798.01
Current Ratio ratio5.640.872.158.9519.1713.4010.1818.798.01

Cash flow, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/2018
Net Income-10.08-9.84-10.57-20.66-14.29-15.71-26.43-15.57-9.91
Depreciation--0.00-100.0%0.03-25.0%0.040.0%0.04-20.0%0.05-16.7%0.06+100.0%0.03
Other Funds (Non Cash)0.781.45+178.8%0.52-95.4%11.32+1450.7%0.73-56.8%1.69-82.0%9.39+1576.8%0.56-45.6%1.03
Funds from Operations-9.30-8.39-10.05-9.31-13.51-13.98-16.99-14.94-8.85
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.91-0.86-159.3%1.45-28.2%2.02-1.72-437.3%0.51+1175.0%0.04-97.9%1.93-0.23
Cash from Operating Activities-10.21-9.25-8.60-7.29-15.23-13.47-16.95-13.01-9.08
Capital Expenditures0.000.000.000.00-0.13-0.040.00-0.03-0.12
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00-100.0%0.06+500.0%0.010.000.00-0.00
Purchase or Sale of Investments4.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00-
Sale Or Maturity of Investments4.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.00-1.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities4.000.000.00-0.94-0.12-0.040.00-0.03-0.12
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock15.1017.65+164.6%6.67+684.7%0.85+1114.3%0.07-99.7%23.67+43.3%16.52+45.6%11.35-51.6%23.45
Repurchase of Common Pref Stock0.000.000.000.000.00-5.640.000.000.00
Sale of Common Pref Stock15.1017.65+164.6%6.67+684.7%0.85+1114.3%0.07-99.8%29.30+77.4%16.52+45.6%11.35-51.6%23.45
Proceedsfrom Stock Options15.0215.02+125.2%6.67+684.7%0.850.000.000.00-100.0%11.350.00
Issuance or Reduction of Debt, Net-3.00-0.87-0.69-0.57-0.56-0.52-0.20-0.25-0.20
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities12.1016.78+180.6%5.98+2035.7%0.28-0.49-102.1%23.14+41.8%16.32+47.0%11.10-52.3%23.25
Net Change in Cash5.897.53-2.62-7.94-15.84-264.5%9.63-0.63-1.94-113.8%14.04
Free Cash Flow-10.21-9.25-8.60-7.29-15.36-13.51-16.95-13.04-9.20
Preferred Dividends (Cash Flow)-0.000.00------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/20242024Q39/30/2024
Cash & Short Term Investments3.86+95.9%6.11+78.7%8.40+876.7%11.40+263.1%1.97+45.9%3.42+65.2%0.86-75.3%3.14-45.6%
Short Term Receivables0.000.000.050.000.000.000.000.00-100.0%
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets1.63+858.8%1.38+206.7%1.61+163.9%1.30+34.0%0.17-37.0%0.45+21.6%0.61+60.5%0.97-51.7%
Total Current Assets5.49+156.5%7.49+93.5%10.07+585.0%12.71+209.2%2.14+32.1%3.87+58.6%1.47-62.0%4.11-47.4%
Net Property, Plant & Equipment0.000.000.000.000.000.000.00-100.0%0.00-100.0%
Total Investments and Advances0.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.00
Other Assets0.000.000.000.00-100.0%0.00-100.0%0.00-100.0%0.00-100.0%1.09+10800.0%
Total Assets5.49+156.5%7.49+93.5%10.07+585.0%12.71+144.4%2.14-21.0%3.87+9.6%1.47-70.4%5.20-34.2%
Short Term Debt Incl. Current Port. of LT Debt0.00-100.0%0.06-97.6%0.23-30.3%0.39-25.0%3.002.55+1861.5%0.33+3.1%0.520.0%
Accounts Payable1.82+43.3%1.25+62.3%1.56+36.8%2.48+64.2%1.27+7.6%0.77+10.0%1.14-8.1%1.51+86.4%
Other Current Liabilities0.000.00-100.0%0.00-100.0%0.00-100.0%0.00-100.0%0.40+344.4%0.21-8.7%0.09+12.5%
Total Current Liabilities1.82-57.4%1.31-64.9%1.79+6.5%2.87+34.7%4.27+209.4%3.73+309.9%1.68-6.7%2.13+52.1%
Long Term Debt0.000.000.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.00
Total Liabilities1.82-57.4%1.31-64.9%1.79+6.5%2.87+34.7%4.27+209.4%3.73+309.9%1.68-6.7%2.13+52.1%
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.00-100.0%0.00-100.0%0.00-100.0%0.00-100.0%1.590.0%
Common Equity3.676.18+4314.3%8.289.83+564.2%-2.130.14-86.4%-0.21-113.3%1.48-69.8%
Total Shareholders Equity3.676.18+4314.3%8.289.83+219.2%-2.13-260.2%0.14-94.7%-0.21-106.6%3.08-52.6%
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity3.676.18+4314.3%8.289.83+219.2%-2.13-260.2%0.14-94.7%-0.21-106.6%3.08-52.6%
Total Liabilities & Stockholders Equity5.49+156.5%7.49+93.5%10.07+585.0%12.71+144.4%2.14-21.0%3.87+9.6%1.47-70.4%5.20-34.2%
Book Value Per Share per share0.811.41+642.1%1.942.38-49.9%-2.590.19-97.3%-0.51-103.3%4.75-91.7%
Tangible Book Value Per Share per share0.811.41+642.1%1.942.38-49.9%-2.590.19-97.3%-0.51-103.3%4.75-91.7%
Full-Time Employees people--30.0%---3-40.0%-
Price to Book Ratio ratio0.430.400.33-0.5119.8632.75-21.912.41
Return on Assets %-264.23-173.03-170.58-121.78-424.84-279.18-328.26-304.75
Return on Equity %-1,307.06-311.00-243.94-168.95--748.05-714.95-417.05
Return on Invested Capital %-68.89-35.61-27.61-31.19--1,610.16--80.03
Quick Ratio ratio3.015.735.644.420.501.040.871.93
Current Ratio ratio3.015.735.644.420.501.040.871.93

Cash flow, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/20242024Q39/30/2024
Net Income-2.53-2.20-2.29-3.07-2.27-2.22-3.35-2.46
Depreciation------0.000.00
Other Funds (Non Cash)0.02-96.6%0.02-83.3%0.74+1133.3%0.01-97.0%0.59+883.3%0.12+71.4%0.06-99.4%0.33-13.2%
Funds from Operations-2.51-2.18-1.55-3.06-1.69-2.09-3.29-2.13
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital0.32-13.5%-0.02-1.29-201.6%0.08-50.0%0.37-47.1%-0.021.27+49.4%0.16+33.3%
Cash from Operating Activities-2.19-2.20-2.84-2.98-1.31-2.11-2.02-1.97
Capital Expenditures0.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00-100.0%0.00-100.0%
Purchase or Sale of Investments0.004.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.004.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities0.004.000.000.000.000.000.000.00-100.0%
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.000.00
Change in Capital Stock0.000.08-97.0%-0.0015.02+287.1%0.00-100.0%2.64+43.5%0.003.88+356.5%
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.000.08-97.0%-0.0015.02+287.1%0.00-100.0%2.64+43.5%0.003.88+356.5%
Proceedsfrom Stock Options0.000.00-100.0%0.00-100.0%15.02-2.642.646.670.00-100.0%
Issuance or Reduction of Debt, Net-0.06-0.17-108.4%-0.17-2.61-0.132.03-0.26-0.12
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities-0.06-0.09-101.9%-0.1712.41+229.2%-0.13-115.9%4.67+183.0%-0.263.77+416.4%
Net Change in Cash-2.241.71-33.2%-3.009.43+423.9%-1.452.56-2.281.80
Free Cash Flow-2.19-2.20-2.84-2.98-1.31-2.11-2.02-1.97

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3018.57%0.8M4.5M29.11K
2026-10-1518.60%0.8M4.5M29.55K
2026-09-3018.70%0.8M4.5M30.37K
2026-09-1517.92%0.8M4.5M32.25K
2026-08-3117.66%0.8M4.5M38.27K
2026-08-1417.53%0.8M4.5M36.58K
2026-07-3117.36%0.8M4.5M42.28K
2026-07-1517.40%0.8M4.5M49.10K
2026-06-3017.22%0.8M4.5M55.19K
2026-06-1516.73%0.8M4.5M69.58K
2026-05-2915.79%0.7M4.5M130.84K
2026-05-1514.62%0.7M4.5M245.36K
2026-04-3015.83%0.7M4.3M252.41K
2026-04-1516.28%0.7M4.3M540.28K
2026-03-3116.71%0.7M4.3M536.49K
2026-03-1318.39%0.8M4.3M526.47K
2026-02-2713.77%0.6M4.1M465.10K
2026-02-1311.08%0.5M4.1M351.29K
2026-01-3012.66%0.5M4.1M344.60K
2026-01-151.40%0.1M4.1M65.66K

Option chain

expiry 2026-11-13
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-09-168-KCurrent report2026-09-16SEC
2026-08-288-KCurrent report2026-08-26SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-073Initial statement of beneficial ownership of securities2026-07-01SEC
2026-07-068-KCurrent report2026-06-29SEC
2026-05-20DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-20DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-20SEC
2026-05-198-KCurrent report2026-05-18SEC
2026-05-08PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-08SEC
2026-05-0810-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-04-138-KCurrent report2026-04-13SEC
2026-03-318-KCurrent report2026-03-27SEC
2026-03-20EFFECTEffectiveness filing by commission orderSEC
2026-03-19CORRESPSEC
2026-03-19S-3/ASEC
2026-03-1610-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-118-KCurrent report2026-03-10SEC
2026-01-27UPLOADUpload SubmissionSEC
2026-01-22S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-01-228-KCurrent report2026-01-22SEC
2026-01-224/A2025-12-11SEC
2026-01-21SCHEDULE 13GSEC
2026-01-208-KCurrent report2026-01-20SEC
2025-12-154Statement of changes in beneficial ownership of securities2025-12-11SEC
2025-12-158-KCurrent report2025-12-11SEC
2025-12-154Statement of changes in beneficial ownership of securities2025-12-11SEC
2025-12-154Statement of changes in beneficial ownership of securities2025-12-11SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-12001981
2025-110000

Institutional holders

Manager% owned
HUB Investment Partners, LLC0.89%
GEODE CAPITAL MANAGEMENT, LLC0.52%
25 LLC0.51%
JANE STREET GROUP, LLC0.28%
Tower Research Capital LLC0.10%
St. Johns Investment Management Company, LLC0.04%
CITIGROUP INC0.03%
BlackRock, Inc.0.02%
UBS Group AG0.01%
FMR LLC0.00%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.50%

OakChart. OGEN. Cached 15 minutes. Terms

Some panels did not load: ratings.